<?xml version="1.0" encoding="UTF-8"?>
<p>Current therapeutic strategies are primarily used for prophylaxis and treatment. One category of anti-influenza drugs, neuraminidase inhibitors (NAI), inhibits influenza virus neuraminidase reducing viral shedding within the respiratory tract [
 <xref rid="B16-biomolecules-11-00010" ref-type="bibr">16</xref>]. Oseltamivir and zanamivir have been approved in many countries, while peramivir and laninamivir are approved in Japan, and peramivir is approved in China and Korea [
 <xref rid="B17-biomolecules-11-00010" ref-type="bibr">17</xref>]. Another category, which includes M2 channel blockers amantadine and rimantadine, functions by blocking the viral RNA uncoating within infected cells and preventing its replication by disrupting the function of the transmembrane domain of the viral M2 protein [
 <xref rid="B16-biomolecules-11-00010" ref-type="bibr">16</xref>].
</p>
